<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363272</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01828</org_study_id>
    <secondary_id>ADVL0517</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <secondary_id>CDR0000491407</secondary_id>
    <nct_id>NCT00363272</nct_id>
  </id_info>
  <brief_title>Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma</brief_title>
  <official_title>A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of ispinesib in treating young&#xD;
      patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy,&#xD;
      such as ispinesib, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and recommended phase II dose of ispinesib in&#xD;
      pediatric patients with refractory solid tumors or lymphoma.&#xD;
&#xD;
      II. Define and describe the toxicities of ispinesib in these patients. III. Characterize the&#xD;
      pharmacokinetics of ispinesib in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Define, preliminarily, the antitumor activity of ispinesib. II. Determine the relationship&#xD;
      between CYP3A4 gene polymorphisms and pharmacokinetics in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28&#xD;
      days for 24 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ispinesib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients undergo blood and tumor sample collection periodically for pharmacokinetic and gene&#xD;
      polymorphism correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT, graded according to NCI CTCAE version 3.0</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Choroid Plexus Tumor</condition>
  <condition>Childhood Craniopharyngioma</condition>
  <condition>Childhood Grade I Meningioma</condition>
  <condition>Childhood Grade II Meningioma</condition>
  <condition>Childhood Grade III Meningioma</condition>
  <condition>Childhood High-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Infratentorial Ependymoma</condition>
  <condition>Childhood Low-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Spinal Cord Neoplasm</condition>
  <condition>Childhood Supratentorial Ependymoma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Brain Tumor</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ispinesib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CK0238273</other_name>
    <other_name>SB-715992</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy at either original diagnosis or relapse, including&#xD;
             the following:&#xD;
&#xD;
               -  Solid tumor, including primary CNS tumors&#xD;
&#xD;
                    -  Neurologic deficits in patients with CNS tumors must have been relatively&#xD;
                       stable for ≥ 1 week&#xD;
&#xD;
                    -  Patients with CNS tumors must be on stable or decreasing doses of&#xD;
                       dexamethasone for the past 7 days&#xD;
&#xD;
                    -  Histology requirement waived for intrinsic brain stem tumors&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No known curative therapy or no therapy proven to prolong survival with an acceptable&#xD;
             quality of life exists&#xD;
&#xD;
          -  Patients with known bone marrow metastases are eligible for study but are not&#xD;
             evaluable for hematologic toxicity&#xD;
&#xD;
               -  Not known to be refractory to red blood cell or platelet transfusions&#xD;
&#xD;
          -  Karnofsky performance score (PS) 60-100% (&gt; 10 years of age) or Lansky PS 60-100% (≤&#xD;
             10 years of age)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (transfusion independent, defined as not receiving&#xD;
             platelet transfusions within a 7-day period prior to study enrollment)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR&#xD;
             creatinine based on age as follows:&#xD;
&#xD;
               -  No greater than 0.8 mg/dL (≤ 5 years of age)&#xD;
&#xD;
               -  No greater than 1.0 mg/dL (6 to 10 years of age)&#xD;
&#xD;
               -  No greater than 1.2 mg/dL (11 to 15 years of age)&#xD;
&#xD;
               -  No greater than 1.5 mg/dL (&gt; 15 years of age)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  ALT ≤ 45 U/L&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or&#xD;
             radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  More than 1 week since prior growth factors, including those that support platelet or&#xD;
             WBC number or function&#xD;
&#xD;
          -  At least 1 week since prior biologic agents&#xD;
&#xD;
          -  At least 2 weeks since prior local, palliative, small-port external-beam radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior total body irradiation (TBI), craniospinal radiotherapy,&#xD;
             or radiotherapy to ≥ 50%of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy (i.e., skull,&#xD;
             spine, pelvis, or ribs)&#xD;
&#xD;
          -  At least 3 months since prior stem cell transplantation or rescue without TBI&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy, radiotherapy,&#xD;
             immunotherapy, or biologic therapy&#xD;
&#xD;
          -  No concurrent enzyme-inducing anticonvulsants, including any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Felbamate&#xD;
&#xD;
               -  Primdone&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
          -  No concurrent agents that inhibit CYP3A4, including any of the following:&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Voriconazole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Sills</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

